Shares of Myokardia Inc (NASDAQ:MYOK) were up 6.7% during mid-day trading on Tuesday . The company traded as high as $53.25 and last traded at $52.90. Approximately 702,200 shares traded hands during mid-day trading, an increase of 16% from the average daily volume of 605,933 shares. The stock had previously closed at $49.60.
Several research firms recently weighed in on MYOK. Zacks Investment Research cut Myokardia from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Credit Suisse Group reissued an “outperform” rating and set a $55.00 price target (up from $45.00) on shares of Myokardia in a report on Tuesday, September 19th. TheStreet cut Myokardia from a “c” rating to a “d+” rating in a report on Friday, November 3rd. JPMorgan Chase & Co. began coverage on Myokardia in a report on Tuesday, December 12th. They set an “overweight” rating and a $54.00 price target for the company. Finally, BidaskClub cut Myokardia from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $54.83.
The stock has a market cap of $1,890.70, a price-to-earnings ratio of -69.60 and a beta of 4.21.
In other Myokardia news, insider Anastasios Gianakakos sold 3,000 shares of the firm’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $41.09, for a total transaction of $123,270.00. Following the transaction, the insider now owns 512,117 shares in the company, valued at approximately $21,042,887.53. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Jake Bauer sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total value of $225,000.00. Following the transaction, the insider now owns 56,777 shares in the company, valued at approximately $2,554,965. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 836,626 shares of company stock worth $35,146,501. Corporate insiders own 33.40% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Myokardia by 11.5% during the 2nd quarter. Vanguard Group Inc. now owns 764,919 shares of the biotechnology company’s stock worth $10,020,000 after acquiring an additional 78,800 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Myokardia by 103.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 476,575 shares of the biotechnology company’s stock valued at $6,243,000 after purchasing an additional 242,408 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Myokardia by 2,151.7% in the 3rd quarter. Wells Fargo & Company MN now owns 417,439 shares of the biotechnology company’s stock valued at $17,887,000 after purchasing an additional 398,900 shares during the last quarter. VHCP Management II LLC bought a new position in shares of Myokardia in the 3rd quarter valued at $11,355,000. Finally, RTW Investments LP bought a new position in shares of Myokardia in the 3rd quarter valued at $10,882,000. Hedge funds and other institutional investors own 63.61% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Myokardia (MYOK) Trading Up 6.7%” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.com-unik.info/2018/01/16/myokardia-myok-trading-up-6-7.html.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.